Sun Pharma gets approval for Winlevi in Australia EP News Bureau Mar 19, 2024 Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Sun Pharma Canada launches WINLEVI for acne EP News Bureau Sep 27, 2023 WINLEVI is the first and only topical androgen receptor inhibitor
Cosmo, Glenmark signs distribution and license pacts for Winlevi in Europe, South Africa EP News Bureau Sep 27, 2023 Cassiopea will receive an upfront payment of $5 million, in addition to double-digit regulatory and sales milestones as well as…
Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI EP News Bureau Jul 26, 2022 The new agreement includes Japan, Australia, New Zealand, Brazil, Mexico and Russia
Sun Pharma launches acnce treatment cream in US Press Trust of India Nov 5, 2021 Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years, Sun Pharma said in a…
Sun Pharma and Cassiopea announce expiry of HSR Act process and consummation of Winlevi agreement EP News Bureau Aug 31, 2021 Sun Pharma now has the exclusive right to commercialse Winlevi in the United States and Canada. Cassiopea will be the exclusive…
Sun Pharma and Cassiopea SpA sign license and supply agreements for Winlevi EP News Bureau Jul 26, 2021 Winlevi is expected to be available in the US in Q4 calendar 2021
US FDA approves Winlevi, topical acne treatment from Cassiopea EP News Bureau Aug 28, 2020 Reportedly, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago